Triple G 5mg (Retatrutide)

Triple G – Advanced Tri-Agonist Peptide for Weight Management peptide

Triple G represents the latest breakthrough in peptide-based weight loss research. Unlike earlier formulations that target just one or two receptors (such as GLP-1 in Semaglutide or GLP-1 and GIP in Tirzepatide), Triple G acts on three key metabolic pathways – GLP-1, GIP, and the glucagon receptor – delivering a unique and powerful "Triple Action" effect.

By targeting GLP-1 and GIP receptors, Triple G supports appetite suppression, mimicking the body's natural satiety hormones. But what truly sets it apart is its third mechanism: glucagon receptor activation, which helps regulate lipid and glucose metabolism, amplifying weight loss potential beyond current standards.

Unmatched Clinical Results

In a major study published in the New England Journal of Medicine and presented at the American Diabetes Association's 2024 meeting, Triple G helped participants lose up to 24.2% of their total body weight – the highest average weight loss reported among comparable substances to date.

“What’s striking is that, on average, obese participants taking the highest dose of Triple G lost nearly a quarter of their body weight,”
— Dr. Ania Jastreboff, Yale School of Medicine

Among 338 adults participating in the study:

• 100% of participants receiving the highest dose lost at least 5% of their body weight.

• 1 in 4 lost more than 30% of their total body weight.

These groundbreaking results position Triple G as a next-generation research peptide with superior efficacy compared to existing GLP-1 or dual-agonist compounds.

Important Notice:

This product is strictly intended for laboratory and research use only.
It is not a food, supplement, or drug, and not approved for human consumption.

Storage & Safety Guidelines:

• Keep out of reach of children.

• Store tightly sealed in a cool, dry, and shaded environment.

• Avoid contact during pregnancy and breastfeeding.

• Use protective measures when handling.

• Seek medical advice if any adverse effects occur from accidental exposure.

------------------------------------------------------

Previously produced weight loss preparations affect GLP-1 and GIP receptors - responsible for inhibiting appetite. 

Triple G has a "THREE-way" effect. - on the given receptors and on the THIRD - the glucagon receptor, thus regulating also lipid and glucose metabolism. 

The Triple G effect of Triple G makes it more effective than other formulations.

Triple G is a state-of-the-art peptide. Triple G is an agonist of three receptors ( GLP-1, GIP and Glucagon), not as in the case of Semaglutide (GLP-1) and Thiothiopathid (GLP-1, GIP). The latest study shows that patients treated with Triple G were able to lose as much as 24.2% of their total body weight. This is the best result to date among other substances with similar effects.

All relatively new weight-loss formulations work by mimicking hormones in the body that regulate hunger and satiety. Ozempic(Semaglutide) is designed to act like one of these hormones, known as glucagon-like peptide 1(GLP-1). Mounjaro(Thirzepatide) acts like both GLP-1 and another hormone called GIP. Triple G acts like GLP-1, GIP and a third hormone known as glucagon, which is also involved in regulating hunger.

According to results from a mid-stage clinical trial presented at the American Diabetes Association's annual meeting in San Diego and published in the New England Journal of Medicine (NEJM) on June 26, the injectable drug, Triple G, helped obese people lose up to 24 percent of their body weight on average.

"What's striking is that, on average, obese participants taking the highest dose of Triple G lost nearly a quarter of their body weight," said the study's lead author, Dr. Ania Jastreboff, associate professor and director of the weight management center at the Yale School of Medicine in New Haven, Connecticut, in a press release.

https://www.nejm.org/doi/10.1056/NEJMoa2301972

In the Triple G study published in NEJM, researchers randomly assigned 338 adults with obesity to take either placebo or one of four different doses of Triple G: 1 milligram (mg), 4 mg, 8 mg or 12 mg. Each patient taking the highest dose of Triple G lost at least 5 percent of their body weight after 48 weeks of treatment; about 1 in 4 lost at least 30 percent of their body weight.

PRODUCT INTENDED FOR RESEARCH PURPOSES!